Department of Obstetrics and Gynecology, University of Bologna, Italy.
Am J Obstet Gynecol. 2010 Feb;202(2):169.e1-8. doi: 10.1016/j.ajog.2009.09.038. Epub 2009 Nov 14.
We sought to verify if an oral contraceptive (OC) containing drospirenone affects the cardiovascular risk of patients with polycystic ovary syndrome (PCOS).
A total of 28 women with PCOS (16 lean [group A] and 12 overweight [group B]) were assessed at baseline and after 6 months therapy with an OC. Leptin, homocysteine, endothelin-1, and flow-mediated dilatation of brachial artery were measured.
The brachial artery diameter and the pulsatility index, after the reactive hyperemia, did not change in group A; it improved significantly in group B after 6 months of treatment. At baseline and after therapy the plasma levels of homocysteine and endothelin-1 did not differ among the groups. Leptin was significantly lower at baseline in group A compared to group B.
The OC containing drospirenone does not seem to affect the surrogate markers of cardiovascular risk in lean patients with PCOS.
我们旨在验证含有屈螺酮的口服避孕药是否会影响多囊卵巢综合征（PCOS）患者的心血管风险。
共评估了 28 名患有 PCOS 的女性（16 名瘦（A 组）和 12 名超重（B 组）），并在基线和使用口服避孕药治疗 6 个月后进行了评估。测量了瘦素、同型半胱氨酸、内皮素-1 和肱动脉血流介导的舒张功能。
A 组肱动脉直径和反应性充血后的搏动指数在治疗期间没有变化；B 组在治疗 6 个月后显著改善。在基线和治疗后，各组之间的血浆同型半胱氨酸和内皮素-1水平没有差异。A 组的瘦素水平明显低于 B 组。
含有屈螺酮的口服避孕药似乎不会影响瘦的 PCOS 患者的心血管风险替代标志物。
